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Abstract
Background: Estimation of plasma cell infiltrates in bone marrow aspirates (BMA) and bone marrow biopsy (BMB) is a 
standard method in the diagnosis and monitoring of multiple myeloma (MM). Plasma cell fraction in the bone marrow 
is therefore critical for the classification and optimal clinical management of patients with plasma cell dyscrasias. The 
aim of the study was to compare the percentage of plasma cells obtained by both methods with the patient clinical 
parameters and survival.
Methods: This retrospective study included BMA and BMB of 59 MM patients. The conventional differential count was 
determined in BMA to estimate the percentage and cytologic grade of plasma cells. The pattern of neoplastic 
infiltration and percentage of plasma cells were estimated on CD138 immunostained BMB slides microscopically and 
by computer-assisted image analysis (CIA).
Results: Significantly higher values of plasma cell infiltrates were observed in pathologist (47.7 ± 24.8) and CIA (44.1 ± 
30.6) reports in comparison with cytologist analysis (30.6 ± 17.1; P < 0.001 and P < 0.0048, respectively). BMB 
assessment by pathologist counting and using CIA showed strongest correlation (r = 0.8; P < 0.0001). Correlation was 
also observed between the pathologist and cytologist counts (r = 0.321; P = 0.015) as well as comparing the 
percentage of plasma cells in BMA and CIA (r = 0.27; P = 0.05). Patients with clinical stage I/II had a significantly lower 
CIA plasma cell count than those with clinical stage III (P = 0.008). Overall survival was shorter in patients with more 
than 25% of atypical plasma cell morphology estimated in BMA (P = 0.05) and a higher percentage of tumor cell 
infiltrates estimated by the pathologist and CIA (P = 0.0341 and P = 0.013, respectively).
Conclusion: Study results suggested the combined analyses to be useful as a routine procedure to achieve more 
accurate and informative diagnostic data.
Introduction
Bone marrow analysis is an important element in estab-
lishing the diagnosis of multiple myeloma (MM), regard-
less of the indicative immunology or radiology findings
[1,2]. It provides necessary information on the level of
bone marrow involvement by plasma cells and its mor-
phological specificities [2]. Minor and major criteria for
the diagnosis according to the definition of the WHO
classification include different categories of the bone
marrow plasma cell count: a shift from 10%-30% group to
>30% group equals shift from minor to major criteria,
while <10% group does not contribute to the diagnosis
[3]. In addition, plasma cell quantification is used in the
evaluation of morphological remission [4] and minimal
residual disease in MM patients [5]. A high percentage of
plasma cells infiltration in bone marrow have been also
recognized as a reliable predictor of relapse in cases of
treated MM, as well as plasma cell microaggregates
detected by immunohistology [6]. Plasma cell fraction in
the bone marrow is therefore critical for the classification
and optimal clinical management of patients with plasma
cell dyscrasias.
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Bone marrow aspirate (BMA) is essential for appropri-
ate evaluation of plasma cell differentiation. On the basis
o f  p l as m a  c e l l  m o rp h o l ogy  i n  B MA,  m y e l o m as  ca n  be
classified into mature, intermediary, immature and plas-
mablastic [7]. It has been demonstrated that this division
correlates with patient survival, since those with plas-
mablastic morphology have median survival of 10
months versus 35 months for all other types among which
no significant difference in survival was observed [7,8]. In
c o m p a r i s o n  w i t h  B M A ,  t r e p h i n e  b o n e  m a r r o w  b i o p s y
(BMB) is not most suitable for the analysis of atypical
plasma cells because of very difficult morphology identi-
fication of plasmablastic, lymphoid, lobated nucleus and
polymorphic plasma cells.
On the other hand, plasma cell infiltrates in bone mar-
row with increased reticulum fibers that can be observed
i n  n e a r l y  9 %  o f  M M  a r e  p r e f e r a b l y  e s t i m a t e d  i n  B M B
rather than BMA because reticuloplasia often leads to
scanty cellular aspirates. In addition, studies have shown
BMB to enable plasma cell infiltrate classification into
interstitial, nodular and diffuse types [9,10]. The amount
of bone infiltrate varies from small clusters in otherwise
normocellular bone marrow up to diffuse 100% bone
marrow infiltration. The type of infiltration pattern is in
proportion with the stage of disease. The interstitial and
nodular patterns are observed when hematopoiesis is still
preserved. In contrast, diffuse infiltration results in sup-
pression of hematopoiesis. Transformation from intersti-
tial or nodular towards diffuse infiltrate is observed as the
disease progresses.
Since accurate quantification of bone marrow plasma
cells is an important step in the diagnosis and post-treat-
ment assessment of plasma cell dyscrasias, the aim of the
present study was to contribute to the current view of the
importance of evaluating both BMA and BMB. At the
same time, the value of image analyses in the diagnostic
work-up remains to be determined. Thus, another objec-
tive of the study was to compare the plasma cell percent-
age estimated in BMA and in CD138 stained BMB
evaluated microscopically or by computer-assisted digital
image analysis (CIA), and then to compare these values
with the patient clinical parameters, therapy response
and survival.
Patients and Methods
This retrospective study included 59 patients diagnosed
w i t h  M M  a t  D e p a r t m e n t  o f  H e m a t o l o g y ,  U n i v e r s i t y
Department of Medicine, Rijeka University Hospital Cen-
ter, during the 2001-2008 period. The diagnosis of MM
was established using the International Myeloma Work-
ing Group 2003 diagnostic criteria [11]. The patient clini-
cal characteristics and clinical stage at the time of
diagnosis according to Durie-Salmon staging system are
presented in Table 1. The median age of patients at diag-
nosis was 71 (range 42-90) years. There were 33 female
and 26 male patients (female to male ratio 1.3:1). The
study was approved by the University of Rijeka Ethics
Committee.
Treatment regimens were heterogeneous but in most
cases included VAD (vincristine, doxorubicin and dexam-
ethasone) infusion chemotherapy, melphalan and predni-
solone, thalidomide alone or with dexamethasone, high-
dose dexamethasone, and bortezomib alone or with dex-
amethasone. Some patients were treated with high-dose
medicamentous therapy and autologous stem cell trans-
plantation. All patients with bone disease were adminis-
tered bisphosphonates and some of them also received
local radiotherapy.
Therapeutic response was defined according to the
EBMT, IBMTR/ABMTR criteria [12]; however, due to the
small number of cases in some response groups, the
patients were divided into two groups: those without any
response or with refractory/progressive disease and those
that achieved some response (complete, partial or mini-
mal) to therapy. The follow up period was minimally 24
months (24-106 months).
Analysis of BMA included determination of plasma cell
percentage from 400-cell differential count on conven-
tional May-Grünwald-Giemsa stained aspirates, and
quantification of atypical plasma cells classified according
to cytologic grading of neoplastic cells as mature and
those expressing signs of atypia (in differentiation)
according to the WHO criteria.
Biopsy specimens (BMB) were fixed in Schaffer fixative
for 24 hours and decalcified in Osteodec over 4-5 hours
(Merck). Routine hemalaun-eosin (HE) staining, Giemsa,
Periodic Acid Schiff (PAS), Gomory and Prussian blue for
Fe detection were used. The presence of marrow fibrosis
and normal hematopoiesis were also recorded.
Slides with 4-μm thick sections were deparaffinized in
xylene, hydrated in graded alcohols and immunohis-
tochemically stained with anti-CD138, Ig kappa and Ig
lambda antibodies. Histology analysis included assess-
ment of bone marrow infiltrate (diffuse, nodular, intersti-
tial), percentage of tumor plasma cells in bone marrow
specimen (CD138) and restriction of Ig light chains,
quantifying the overall marrow cellularity as percentage
of myeloma cells in biopsy specimen.
All slides stained with anti-CD138 were scanned and
analyzed with Alphelys Spot Browser 2 integrated system,
using a software controlled (Alphelys Spot Browser 2.4.4.,
France) stage positioning Nikon Eclipse 50i microscope
mounted 1360 × 1024 resolution Microvision CFW-
1310C digital camera. Overview images were taken at
×20 magnification and analysis images at ×100 magnifi-
cation.Štifter et al. Diagnostic Pathology 2010, 5:30
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Statistical analysis
The difference in average (median) number of plasma cell
counts was tested with exact Mann-Whitney test. The
correlation between the values recorded was assessed
with exact Pearson/Spearman rank coefficient. The prob-
ability values of P < 0.05 were considered statistically sig-
nificant. The Kaplan-Meier method was used to estimate
overall patient survival. The SPSS version 12.0 software
(SPSS, Chicago, IL, USA) was used on all analyses.
Results
Bone marrow plasma cell infiltrates assessed in BMA and 
BMB
In general, CD138 stained BMB consistently demon-
strated greater plasma cell infiltration as compared with
BMA. On image analysis, software detected cells and
bone marrow areas based on their color properties (wave
length, intensity and saturation) and morphometry (size
and shape). The software was programmed to detect sec-
tion area from background empty space, white areas rep-
resenting clear areas of fat cells, homogeneous blue areas
representing bone marrow trabeculae, heterogeneous
cellular marrow area, 'positive' brown cells and 'negative'
blue cells. Counting of CD138 positive and negative cells
was only performed in regions of cellular marrow. Plasma
cell percentage was calculated for each section based on
its positive and negative cell count. Section area, bone
marrow trabeculae area, fat cell area and cellular marrow
area were calculated automatically by the software (Fig-
ure 1).
The median percentage of plasma cell infiltrate
recorded in BMA was 29% (range 3%-68%) and in BMB
50% (range 5%-100%) when assessed by the pathologist
and 39% (range 1%-99%) with the use of CIA. Statistical
analysis with T-test for independent samples showed sig-
nificant difference between BMA and BMB, whereas no
difference was observed between the pathologist and CIA
counts (P = 0.49). More precisely, significantly higher val-
ues were observed in the pathologist's (mean 47.712 ±
24.8) and CIA reports (mean 44.113 ± 30.6) as compared
with the cytologist's report (mean 30.649 ± 17.1; P < 0.001
and P < 0.0048, respectively) (Figure 2a). This discrep-
ancy was mainly present in cases with nodular (8.5%) or
nodular/interstitial (10.2%) pattern of bone marrow
involvement and marked reticuloplasia.
Plasma cells with cytologic atypia on BMA were
observed in 45.6% (26/58) of cases. Comparison by Pear-
son test yielded a correlation of plasma cell quantification
between BMA and CD138 stained BMB sections
reviewed microscopically by the pathologist and CIA.
However, the two methods of BMB assessment, i.e.
counting by the pathologist and by use of CIA, showed
highest correlation (r = 0.8; P < 0.0001). Correlation was
also recorded between plasma cell assessments done by
the pathologist and cytologist (r = 0.321; P = 0.015), and
between plasma cells in BMA and CIA (r = 0.27; P = 0.05)
(Figure 2b).
Comparison of plasma cell infiltrates with clinical 
parameters
For statistical analysis, patients were regrouped into clini-
cal stage I/II versus stage III. Mann-Whitney test yielded
significant difference for CIA plasma cell count (P  =
0.008) (Table 2). Kaplan-Meier survival analysis (months)
showed a mean survival time (limited to median) of 25
months. When patients were divided in two groups, with
high and low plasma cell count, according to median per-
centage of plasma cell infiltrate, e.g. 50% in BMB, 39% in
CIA, and 29% in BMA, the analysis showed difference in
survival when plasma cell count reported by the patholo-
gist (P = 0.0341) (Figure 3a) and CIA (P = 0.013) (Figure
3b), but not with the cytologist's report (P = 0.951). As
the values of atypical plasma cell increased by more than
25% (of atypical plasma cells in whole plasma cell count),
Table 1: Clinical characteristics of multiple myeloma (MM) patients
Characteristic No. (%) of MM patients
Sex Male 26 (44%)
Female 33 (56%)
M:F 1:1.3
Age (yrs) Range 42-90
Median 71
Clinical stage I 8 (13.6%)
II 23 (39.0%)
III 28 (37.4%)
Total 59 (100%)Štifter et al. Diagnostic Pathology 2010, 5:30
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survival time significantly decreased (P = 0.05) (Figure
3c).
Discussion
The quantification of plasma cells in bone marrow is an
essential step in the diagnosis of plasma cell dyscrasias.
At this point, one can argue that the acquired bone mar-
row particles dispersed in BMA are sufficient for micro-
scopic diagnosis in most cases [5,12]. However, MM is a
focal process, in our study in nearly 20% of cases, and it
may have some impact on the accuracy and reliability of
the plasma cell percentage assessment in BMA. As dem-
onstrated elsewhere, there are notable discrepancies and
a relatively poor correlation in determining the percent-
age of bone marrow plasma cells between BMA and BMB
[13]. So, many studies have been conducted in order to
recommend the most reliable method of estimating
plasma cell infiltrates that could be routinely performed.
In the present study, an immunohistochemistry
method with CD138 on BMB was used. The utility of
plasma cell quantification by CD138 immunohistochem-
istry has been widely supported [6,14-16]. It has been
generally accepted as the most sensitive method for
quantifying plasma cell burden, especially in patients
with low percentage of plasma cells on BMA examina-
tion. In addition, estimates of plasma cell percentage
using CD138 sections demonstrated the highest inter-
observer concordance [17]. In our study, CD138 often
revealed a higher plasma cell percentage (50% and 39% as
assessed microscopically or by CIA analysis, respectively)
than that estimated in BMA (29%). As mentioned above,
it was generally observed in cases with nodular plasma
cell infiltration and marrow fibrosis. One of the possible
reasons for this discrepancy is also the fact that myelo-
gram is performed in thin parts of specimen that only
contain individual, clearly visible cells, and not in marrow
particles where plasma cells are often grouped, and evalu-
ated in BMB. Yet, cytology reports contain information
whether there is such a focal aggregation of plasma cells,
although this part is not included in the percentage of
plasma cells shown in myelogram, so it is unsuitable for
statistical comparison and it was left out. The discrep-
ancy has been previously reported on plasma cell assess-
ment in BMB between HE and CD138 stained sections
[18]. According to other reports and our experience,
CD138 sections should be considered for routine use in
the estimation of plasma cell load in bone marrow.
Besides, BMB is strongly recommended and adequately
examined with immunohistochemistry during follow up
of MM, as reported elsewhere [18]. CD138 stained sec-
Figure 1 Computer-assisted image analysis. Screen shoots of scanned sample, with detailed histology images of (a) interstitial, (b) nodular and (c) 
diffuse type of bone marrow infiltration showing color based sample analysis.Štifter et al. Diagnostic Pathology 2010, 5:30
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tions allow for excellent assessment of plasma cell counts
and distribution in BMB, and can highlight a pattern of
distribution indicative of neoplastic infiltration/recur-
rence in the absence of increased overall bone marrow
plasma cell percentage [6,17]. This finding may be of par-
ticular importance in the context of post-therapeutic
hypocellular marrows where the plasma cell infiltrates
may be small and arranged in microaggregates, which
may lead to sampling error [6].
The aim of this study was also to highlight the use of
CIA, which demonstrated high reproducibility of bone
marrow plasma cell quantification [19,20]. This might be
of critical importance for the diagnosis, clinical manage-
ment and prognosis when plasma cell counts low, which
makes exact quantification difficult. As shown previously,
on computer image analysis, plasma cell quantification
was based on color ratios, which reflected the amount of
brown CD138 positivity as a fraction of cellular marrow.
The system did not actually compute the percentage of
Figure 2 Analysis of plasma cell count in bone marrow aspirate (BMA) and bone marrow biopsy (BMB). (a) Box and whisker plot (T-test) show-
ing significant difference in plasma cell count between BMA and BMB analysis. Higher values were observed in pathologist (BMB) (mean 47.712 ± 24.8) 
and computer image analysis (CIA) (mean 44.113 ± 30.6) as compared with (BMA) cytologist report (mean 30.649 ± 17.1) (P < 0.001 and P < 0.0048, 
respectively). (b) Scatter plots showing correlation between CIA and BMB; BMA and BMB; CIA and BMA. Correlation of BMB assessment: pathologist 
and CIA counting (r = 0.8; P < 0.0001), pathologist and cytologist counting (r = 0.321; P = 0.015), and percentage of plasma cells in BMA and CIA (r = 
0.27; P = 0.05).
Figure 3 Kaplan-Meier survival analysis (months) showing difference in patients survival (when plasma cell count divided in high and low 
groups according the median) obtained by (a) pathologist report (BMB) (P = 0.0341), (b) computer-assisted (CIA) report (P = 0.013), and (c) 
cytologist (BMA) report (P = 0.05), when cut off for atypical plasma cell count was set at 25%.Štifter et al. Diagnostic Pathology 2010, 5:30
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labeled cells but rather assessed the relative area of posi-
tive stain. With very high levels of plasma cell involve-
ment, the plasma cell area percentage scores obtained by
computer tended to be lower than the visual estimates of
bone marrow plasma cell percentage using CD138
stained sections. Conversely, with low-level involvement
by plasma cells, the plasma cell area percentage scores
obtained by computer were higher than those obtained
by visual estimation. This suggests that the computer may
be more sensitive in detecting plasma cell percentage
than visual method. As observed in this analysis, the
mean percentage of plasma cells obtained by CIA was
higher as compared with BMA, but lower than micro-
scopic analysis in BMB. However, stronger correlation
was achieved between the pathologist's and CIA counts
than between BMA and CIA.
Numerous prognostic factors have been reported in
patients with MM and among them a high plasma cell
percentage in bone marrow has also been recognized as a
reliable predictor of relapse in cases of treated MM [6]. At
the time of diagnosis, approximately 50% of our patients
had >50% plasma cell infiltration when analyzed on BMB
and nearly the same percentage of MM patients had unfa-
vorable cytologic features, i.e. atypical plasma cell mor-
phology. In 59 patients with follow up data available,
survival assessment using Kaplan-Meier analysis revealed
favorable prognosis for patients with well differentiated
plasma cells and <50% of bone marrow tumor infiltrates
estimated in BMB. Similar findings have been reported in
the literature [21,22]. These findings support the impor-
tance of evaluating BMA and BMB slides in the diagnosis
and monitoring the course of MM, as also suggested by
other authors [14,23,24].
So, a large part of Scudla et al. report is dedicated to
limitations of BMA interpretation, while paying due
attention to indications for and specific benefits of BMB
assessment [25]. According to the authors, the quantita-
tive and cytomorphological evaluation of bone marrow
samples still makes an integral part of the standard algo-
rithm of methods used in MM diagnosis and monitoring,
and requires an extremely qualified approach to BM
specimen collection, smear preparation and precise eval-
uation, including their relevance for clinical interpreta-
t ion [ 25] .  B us s  et a l . c onc lu de  t ha t  bot h bone  m a rr o w
sections and smears should be examined for suspect MM
diagnosis, since neither may be diagnostic alone [26]. Our
results are in accordance with these findings. As each
analysis has its limitations, combined methods applied
whenever possible permit a more thorough approach. At
the same time, the presented results give important infor-
mation on the association between survival and percent-
age of plasma cells infiltration in BMB, which has not
been previously perceived. Accordingly, CD138 immu-
noperoxidase staining can be recommended for routine
assessment of the percentage and kappa and lambda light
chains; furthermore, the fact that bone marrow findings
correlated with clinical findings may potentially be of
predictive value even at the time of establishing the diag-
nosis of MM. Considering the results obtained, we have
to agree with Terpstra et al. that bone marrow biopsy is
superior to bone marrow aspirate for direct assessment of
tumor load in MM [27]. The possible explanation could
be that biopsy offers an insight into the type of infiltration
and thus enables a more accurate prediction.
In conclusion, our results showed reduced survival in
patients with higher percentage of tumor cells and imma-
ture morphology of plasma cells. This result can impli-
cate the necessity of risk-adapted therapy. It would be of
great interest to see whether the novel agents such as
bortezomib, thalidomide or lenalidomide, as well as their
combinations, can overcome the unfavorable impact of
these parameters. This issue will be addressed in our
future study.
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Table 2: Comparison of plasma cell count recorded in bone marrow biopsy (BMB), bone marrow aspirate (BMA) and by 
computer-assisted image analysis (CIA) according to clinical stage
Clinical stage
I, II III P
BMB 44.68 ± 23.5 51.01 ± 26.12 0.239
BMA 27.26 ± 16.0 34.67 ± 17.88 0.136
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